mifepristone has been researched along with Placenta, Retained in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bai, H; Cui, R; Lu, J; Zhang, Z | 1 |
Heikinheimo, O; Mentula, M | 1 |
Willems, FE | 1 |
Li, Q; Liu, M; Mu, YL; Yang, ZL; Yin, FB | 1 |
Hahlin, M; Nielsen, S; Platz-Christensen, J | 1 |
2 trial(s) available for mifepristone and Placenta, Retained
Article | Year |
---|---|
Risk factors of surgical evacuation following second-trimester medical termination of pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Abortifacient Agents, Steroidal; Abortion, Eugenic; Abortion, Therapeutic; Adolescent; Adult; Dilatation and Curettage; Dose-Response Relationship, Drug; Female; Finland; Follow-Up Studies; Hospitals, University; Humans; Maternal Age; Mifepristone; Misoprostol; Placenta, Retained; Pregnancy; Pregnancy Trimester, Second; Risk Factors; Time Factors; Young Adult | 2012 |
Randomised trial comparing expectant with medical management for first trimester miscarriages.
Topics: Abortifacient Agents, Steroidal; Abortion, Spontaneous; Adult; Ambulatory Care; Chorionic Gonadotropin; Female; Humans; Length of Stay; Mifepristone; Pain; Placenta, Retained; Pregnancy; Pregnancy Trimester, First; Progesterone | 1999 |
3 other study(ies) available for mifepristone and Placenta, Retained
Article | Year |
---|---|
The Feasibility of Conservative Management for Morbidly Adherent Placenta Accidentally Encountered after Vaginal Delivery.
Topics: Abortifacient Agents; Adult; Balloon Occlusion; Blood Transfusion; Conservative Treatment; Delivery, Obstetric; Drugs, Chinese Herbal; Feasibility Studies; Female; Humans; Hysterectomy; Methotrexate; Mifepristone; Placenta; Placenta Accreta; Placenta, Retained; Postpartum Hemorrhage; Pregnancy; Retrospective Studies; Uterine Artery Embolization; Vagina | 2017 |
[Pregnancy termination in the second trimester with vaginally administered dinoprostone followed by intravenous sulprostone, for the indication 'foetal congenital defects'; results of a retrospective study].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Dinoprostone; Female; Humans; Mifepristone; Misoprostol; Placenta, Retained; Pregnancy | 2004 |
[Clinical value of transcervical resection under hysteroscope for placental remnants].
Topics: Abortifacient Agents, Nonsteroidal; Adult; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Electrosurgery; Female; Humans; Hysteroscopy; Methotrexate; Mifepristone; Misoprostol; Placenta, Retained; Pregnancy; Retrospective Studies; Treatment Outcome; Ultrasonography | 2007 |